Acadia Pharma (ACAD) Misses Q1 EPS by 10c; Offers FY22 Guidance

Acadia Pharma (NASDAQ: ACAD) reported Q1 EPS of ($0.70), $0.10 worse than the analyst estimate of ($0.60). Revenue for the quarter came in at $115.5 million versus the consensus estimate of $121.92 million.

GUIDANCE:

Acadia Pharma sees FY2022 revenue of $510-560 million, versus the consensus of $540.7 million.

For earnings history and earnings-related data on Acadia Pharma (ACAD) click here.

You May Also Be Interested In

• SanDisk upgraded at JPMorgan after investor day; shares climb
• Instil Bio Inc. (TIL) Misses Q2 EPS by 21c
• CaliberCos Inc (CWD) Misses Q2 EPS by 43c; Offers Guidance